FEEDBACK PLC

Management Reports • Dec 18, 2025

National Storage Mechanism | Additional information

RNS Number : 9970L

Feedback PLC

18 December 2025

The information contained within this announcement is deemed by the Company to constitute inside information pursuant to Article 7 of EU Regulation 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

Feedback plc

Trading Update

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, provides a trading update for the six months to 30 November 2025 (the "Period").

Revenue for the Period is expected to be c. £0.4m (H1 2025: £0.4m). Cash outlook remains in line with expectations and the Company continues to have sufficient cash runway through to mid-2027.

The backdrop is stabilising after last year's uncertainty and disruption across the NHS. During the Period there has been increased focus from policy makers and NHS management on the role of technology and digitisation in reducing NHS waiting times, combined with moves towards neighbourhood healthcare. This is supported by commitments to increase NHS technology spend.

Bleepa is well positioned given its proven capabilities and capacity to address analogue to digital and facilitate hospital to community, combined with its ability to help reduce waiting lists. As last year's disruption passes and given the increasing focus on technology and the flexibility of the Company's solutions, management expects that sales momentum could build around the next tax year, with the Company positioned to scale quickly and effectively.

Dr Tom Oakley, CEO of Feedback plc, said: "The 10-year plan and direction of travel of the NHS are clearly aligned with the solutions we provide. Spending Review funding is due to be released to the NHS frontline for 2026/27, and we believe that this combined with an increasing recognition of the role of technology in healthcare will drive a new phase of commercialisation for Feedback."

--Ends--

Enquiries:

Feedback plc Tom Oakley, CEO Emma Oswick, CFO	+44 (0) 20 3997 7634 [email protected]
Panmure Liberum Limited (NOMAD and Broker) Emma Earl/Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking)	+44 (0)20 7886 2500
Walbrook PR Ltd;	Tel: 020 7933 8780 or [email protected]
Nick Rome/Joe Walker	07748 325 236 or 07407 020 470

About Feedback plc

Feedback plc liberates the data and knowledge from multiple healthcare IT systems and delivers better workflow to enable clinicians to communicate, collaborate and provide the best healthcare for their patients. We connect care settings with diagnostic and other relevant data to drive better, faster, safer decision that improve outcomes for patients.

By linking different clinical systems together into a seamless view of the patient, we can streamline patient pathways and deliver a digital health and diagnostics record across multiple care providers.

Bleepa® is our communication and collaboration platform that displays clinical results at a certified and regulated quality, which enables multi-disciplinary team working and diagnostic-enhanced advice and guidance. CareLocker® is our patient-facing platform that gives patients access and control over their diagnostic and other clinical data.

The Company has a number of growth opportunities domestically and internationally across a range of public and private healthcare markets including the NHS. Our highly scalable software-as-a-service (SaaS) based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

https://feedbackmedical.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TSTBUBDDXXBDGUR